Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
Nippon Shinyaku said on February 7 that the US FDA has accepted its oligonucleotide drug viltolarsen for priority review as a treatment of Duchenne muscular dystrophy (DMD), with a target action date set for the July-September quarter of 2020. The…
To read the full story
Related Article
- Nippon Shinyaku’s DMD Treatment Approved in US
August 17, 2020
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
BUSINESS
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…